Omalizumab for Mast Cell Activation Syndrome
Introduction to Omalizumab
- Omalizumab is an effective treatment option for patients with mast cell activation syndrome (MCAS) experiencing chronic flares, particularly when symptoms are insufficiently controlled by conventional therapies, as recommended by the National Comprehensive Cancer Network 1
- The American College of Allergy, Asthma, and Immunology suggests that omalizumab is specifically indicated for patients with mast cell disorders who have symptoms insufficiently controlled by conventional therapy, including antihistamines and other antimediator agents 1
- Omalizumab is particularly recommended for patients with unprovoked anaphylaxis or those with hymenoptera or food-induced reactions, according to the National Comprehensive Cancer Network 2
Effectiveness and Safety
- Omalizumab can significantly reduce or eliminate anaphylactic episodes in patients with MCAS, as reported by the Journal of Allergy and Clinical Immunology 3
- The medication is effective for reducing symptoms in patients with MCAS, with a particular benefit for vasomotor symptoms, gastrointestinal symptoms, and urinary symptoms, although the strength of evidence is moderate 1
- Clinicians administering omalizumab should be prepared to identify and treat potential anaphylaxis, as warned by the Journal of Allergy and Clinical Immunology 4
Treatment Algorithm
- First-line therapy for MCAS includes H1 and H2 antihistamines, often at higher than standard doses, as recommended by the Journal of Allergy and Clinical Immunology and the National Comprehensive Cancer Network 3, 5
- Second-line therapy involves adding cromolyn sodium for persistent symptoms, particularly for gastrointestinal manifestations, as suggested by the National Comprehensive Cancer Network 5, 1
- Third-line therapy considers leukotriene receptor antagonists or aspirin, and fourth-line therapy considers omalizumab for patients with persistent symptoms, recurrent anaphylaxis, or severe skin manifestations, as recommended by the National Comprehensive Cancer Network and the Journal of Allergy and Clinical Immunology 1, 3